Actavis to Acquire Durata Therapeutics, Inc.

Actavis to Acquire Durata Therapeutics, Inc.

Firm News

On October 6, 2014, WilmerHale client Durata Therapeutics announced that it had entered into a definitive merger agreement with Actavis plc under which a subsidiary of Actavis will commence a tender offer to acquire all of the outstanding shares of Durata common stock for $23 per share in cash, or approximately $675 million in the aggregate, and contingent value rights entitling the holder to receive additional cash payments of up to $5 per share if certain regulatory or commercial milestones related to Durata's lead product DALVANCE™ are achieved. Durata Therapeutics is an innovative pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses.

The WilmerHale team representing Durata Therapeutics includes Corporate Partners Brian Johnson, Jay Bothwick and Joseph Conahan, Senior Associate Chris Barnstable-Brown and Associate Mhairi Collins Immermann, and Tax Partners Kimberly Wethly, Scott Kilgore and Matt Schnall, as well as Senior Associate Ciara Baker.

The complete release with details of the transaction can be found on Durata Therapeutics' site.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.